


衛生署藥物辦公室
藥物註冊及進出口管制部



DEPARTMENT OF HEALTH
DRUG OFFICE
DRUG REGISTRATION AND
IMPORT/EXPORT CONTROL DIVISION
3/F., Public Health Laboratory Centre,
382 Nam Cheong Street, Kowloon, Hong Kong

香港九龍南昌街 382 號公共衛生檢測中心三樓

電話號碼 Tel. No.: 2319 8458
詢問處 Enquiries (852) 2319 8458
傳真號碼 Faxline No. (852) 2803 4962
本署檔案 OUR REF.: DH DO PRIE/7-30/15

BY FAX

25 June 2012

(來函請註明此檔案號碼)
(IN REPLY PLEASE QUOTE THIS FILE REF.)

Dr. Raymond LIANG
President
Hong Kong Academy of Medicine
(Fax Number: 2505 5577)

Dear Dr. LIANG,

EMA: Recommendations on the restriction use of tolperisone medicines

Please kindly note that the European Medicines Agency (EMA) has recommended restricting the use of tolperisone, as the benefit-risk profile for oral tolperisone considered positive only for adults with post-stroke spasticity and negative for injectable tolperisone.

The recommendation followed the review by the Agency's Committee for Medicinal Products for Human Use (CHMP). Taking into account that the risk of hypersensitivity reactions is more significant than previously identified and due to uncertainties in relation to its efficacy in the different indications, the Committee concluded that the benefits of tolperisone outweighed its risks only in the treatment of adults with post-stroke spasticity and only when used as an oral formulation.

EMA advised that tolperisone should not be prescribed for any other indication than post-stroke spasticity in adults and injectable tolperisone is no longer recommended. Patients should be made aware of the possibility of developing hypersensitivity reactions during treatment with tolperisone.


Please refer to EMA's website for details:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/06/news_detail_001540.jsp&mid=WC0b01ac058004d5c1

In Hong Kong, there are 4 registered pharmaceutical products containing tolperisone. All in oral dosage form and are prescription-only medicines. They can be used for the treatment of spasticity and muscle spasms. In view of the EMA's recommendation, the matter will be discussed in the meeting of Registration Committee of the Pharmacy and Poisons Board.

Please encourage your members to report any adverse events caused by the drugs to the Pharmacovigilance Unit of Department of Health (tel. no.: 2319 2920, fax: 2147 0457 or email: adr@dh.gov.hk). For details, please refer to the following website: http://www.drugoffice.gov.hk/eps/root/en/healthcare_providers/adr_reporting/index.html at Drug Office under "Reporting an Adverse Drug Reaction". You may wish to visit the Drug Office's website for subscription and browsing of "Drug News" which is a monthly drug safety digest of drug safety news and information issued by Drug Office.

Yours sincerely,


(Ms. Christine CHEUNG)
for AD(D)

We are committed to providing quality client-oriented service